Among the sirtuins, SIRT1, SIRT3, SIRT4, and SIRT6 have been identified as significant targets for anti-tumor treatments [26]; SIRT4 has been proposed as a tumor-suppressor protein, reducing glutamine entry into mitochondria in response to DNA damage [27,28]. This evidence concerns the gene SIRT3 and neoplasm.